Safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with opioid use disorder.

Autor: Thakrar AP; National Clinician Scholars Program at the Corporal Michael J. Crescenz Veterans Affairs Medical Center, University of Pennsylvania, Philadelphia, USA. apthakrar@pennmedicine.upenn.edu.; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA. apthakrar@pennmedicine.upenn.edu., Uritsky TJ; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, USA., Christopher C; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, USA., Winston A; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Ronning K; School of Nursing, University of Pennsylvania, Philadelphia, USA., Sigueza AL; School of Nursing, University of Pennsylvania, Philadelphia, USA., Caputo A; School of Nursing, University of Pennsylvania, Philadelphia, USA., McFadden R; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Emergency Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA., Olenik JM; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Perrone J; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Delgado MK; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Lowenstein M; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA., Compton P; Center for Addiction Medicine & Policy, University of Pennsylvania, Philadelphia, USA.; Department of Emergency Medicine, Hospital of the University of Pennsylvania, Philadelphia, USA.
Jazyk: angličtina
Zdroj: Addiction science & clinical practice [Addict Sci Clin Pract] 2023 Feb 24; Vol. 18 (1), pp. 13. Date of Electronic Publication: 2023 Feb 24.
DOI: 10.1186/s13722-023-00368-z
Abstrakt: Background: Patients with opioid use disorder (OUD) frequently leave the hospital as patient directed discharges (PDDs) because of untreated withdrawal and pain. Short-acting opioids can complement methadone, buprenorphine, and non-opioid adjuvants for withdrawal and pain, however little evidence exists for this approach. We described the safety and preliminary outcomes of short-acting opioid agonist treatment (sOAT) for hospitalized patients with OUD at an academic hospital in Philadelphia, PA.
Methods: From August 2021 to March 2022, a pharmacist guided implementation of a pilot sOAT protocol consisting of escalating doses of oxycodone or oral hydromorphone scheduled every four hours, intravenous hydromorphone as needed, and non-opioid adjuvants for withdrawal and pain. All patients were encouraged to start methadone or buprenorphine treatment for OUD. We abstracted data from the electronic health record into a secure platform. The primary outcome was safety: administration of naloxone, over-sedation, or a fall. Secondary outcomes were PDDs and respective length of stay (LOS), discharges on methadone or buprenorphine, and discharges with naloxone. We compared secondary outcomes to hospitalizations in the 12 months prior to the index hospitalization among the same cohort.
Results: Of the 23 cases, 13 (56.5%) were female, 19 (82.6%) were 40 years or younger, and 22 (95.7%) identified as White. Twenty-one (91.3%) regularly injected opioids and four (17.3%) were enrolled in methadone or buprenorphine prior to hospitalization. sOAT was administered at median doses of 200-320 morphine milligram equivalents per 24-h period. Naloxone administration was documented once in the operating room, over-sedation was documented once after unsanctioned opioid use, and there were no falls. The PDD rate was 44% with median LOS 5 days (compared to PDD rate 69% with median LOS 3 days for prior admissions), 65% of sOAT cases were discharged on buprenorphine or methadone (compared to 33% for prior admissions), and 65% of sOAT cases were discharged with naloxone (compared to 19% for prior admissions).
Conclusions: Pilot implementation of sOAT was safe. Compared to prior admissions in the same cohort, the PDD rate was lower, LOS for PDDs was longer, and more patients were discharged on buprenorphine or methadone and with naloxone, however efficacy for these secondary outcomes remains to be established.
(© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
Databáze: MEDLINE
Externí odkaz: